Clinical trial NCT04276025 - References

NSCLC — Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma

Citation(s)

•   Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, Mitchell P, Boutros P, John T
  PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS One. 2016 Apr 22;11(4):e0153954. doi: 10.1371/journal.pone.0153954. eCollection 2016.
•   Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA
  Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.
•   Chatziandreou I, Tsioli P, Sakellariou S, Mourkioti I, Giannopoulou I, Levidou G, Korkolopoulou P, Patsouris E, Saetta AA
  Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. PLoS One. 2015 Jul 24;10(7):e0133859. doi: 10.1371/journal.pone.0133859. eCollection 2015.
•   Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ
  Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):133-40. doi: 10.1007/s00259-012-2247-0. Epub 2012 Oct 13. Review.
•   Cook GJR, Azad G, Owczarczyk K, Siddique M, Goh V
  Challenges and Promises of PET Radiomics. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1083-1089. doi: 10.1016/j.ijrobp.2017.12.268. Epub 2018 Jan 31. Review.
•   Fujimoto J, Wistuba II
  Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol. 2014 Jul;31(4):306-13. doi: 10.1053/j.semdp.2014.06.008. Epub 2014 Jun 12. Review.
•   Intlekofer AM, Thompson CB
  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.
•   Khalil FK, Altiok S
  Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. Cancer Control. 2015 Apr;22(2):193-9. Review.
•   Ma W, Gilligan BM, Yuan J, Li T
  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016 May 27;9(1):47. doi: 10.1186/s13045-016-0277-y. Review.
•   Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, Pellot-Barakat C, Soussan M, Frouin F, Buvat I
  LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018 Aug 15;78(16):4786-4789. doi: 10.1158/0008-5472.CAN-18-0125. Epub 2018 Jun 29.
•   O'Flaherty L, Wikman H, Pantel K
  Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. Transl Lung Cancer Res. 2017 Aug;6(4):431-443. doi: 10.21037/tlcr.2017.07.03. Review.
•   Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I
  Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014 Mar;55(3):414-22. doi: 10.2967/jnumed.113.129858. Epub 2014 Feb 18.
•   Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ
  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011 May 20;29(15):2046-51. doi: 10.1200/JCO.2010.33.1280. Epub 2011 Apr 11.
•   Pan ZK, Ye F, Wu X, An HX, Wu JX
  Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015 Mar;7(3):462-70. doi: 10.3978/j.issn.2072-1439.2015.02.13.
•   Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, Zsótér N, Essler M
  Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving pri
•   Pyka T, Gempt J, Hiob D, Ringel F, Schlegel J, Bette S, Wester HJ, Meyer B, Förster S
  Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):133-141. doi: 10.1007/s00259-015-3140-4. Epub 2015 Jul 29.
•   Sharma SV, Bell DW, Settleman J, Haber DA
  Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.
•   Sholl LM
  Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015 Apr;139(4):469-80. doi: 10.5858/arpa.2014-0128-RA. Epub 2014 Sep 25. Review.
•   Sollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M
  PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep. 2017 Mar 23;7(1):358. doi: 10.1038/s41598-017-00426-y. Review.
•   van Helden EJ, Vacher YJL, van Wieringen WN, van Velden FHP, Verheul HMW, Hoekstra OS, Boellaard R, Menke-van der Houven van Oordt CW
  Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2307-2317. doi: 10.1007/s00259-018-4100-6. Epub 2018 Aug 9.
•   Villalobos P, Wistuba II
  Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 2017 Feb;31(1):13-29. doi: 10.1016/j.hoc.2016.08.006. Review.
•   Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H
  ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol. 2013 Apr;37(4):554-62. doi: 10.1097/PAS.0b013e3182758fe6.
•   Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y
  PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017 Aug 31;7(1):10255. doi: 10.1038/s41598-017-10925-7.
•   Zhao Z, Verma V, Zhang M
  Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biol Ther. 2015;16(12):1691-701. doi: 10.1080/15384047.2015.1095407. Review.
•   Zhong A, Xing Y, Pan X, Shi M, Xu H
  Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis. Onco Targets Ther. 2015 Dec 1;8:3595-601. doi: 10.2147/OTT.S91469. eCollection 2015.
•   Zhu QG, Zhang SM, Ding XX, He B, Zhang HQ
  Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget. 2017 Apr 10;8(34):57680-57692. doi: 10.18632/oncotarget.17016. eCollection 2017 Aug 22. Review.
•   Zou W, Wolchok JD, Chen L
  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118. Review.

Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer

Details for clinical trial NCT04276025